Authors
Longjiang Qiao, Xinyu Li, Shuaishuai Xing, Qianwen Guan, Kun Ning, Weijie Han, Luyu Zhang, Anlan Dai, Weiqi Yang, Yinhang Liu, Jason J Kwon, Xin Gao, Haopeng Sun, Yuemin Bian
Published in
Communications chemistry. Jun 15, 2026. Epub Jun 15, 2026.
Abstract
Machine learning-guided virtual screening has the potential to accelerate early-stage drug discovery, but its practical utility is often limited by uncertain generalization to different chemical scaffolds and by insufficient prospective evaluation under realistic experimental constraints. To address these challenges, we conduct a target-driven virtual screening study using TAME-VS against aldo-keto reductase 1C3 (AKR1C3), an enzyme implicated in cancer progression and chemoresistance. By integrating automated target expansion, bioactivity data acquisition, and supervised learning, we construct classification models that leverage homolog-derived information to address data sparsity. Retrospective validation using inhibitor series absent from the training data demonstrates generalization to chemically different scaffolds beyond similarity-based prioritization. Prospective validation on newly designed derivatives shows that model-guided prioritization enriches active inhibitors relative to rational medicinal chemistry design alone under constrained synthesis capacity. S34-1035 and S34-1040 were further identified as potent and selective AKR1C3 inhibitors, and were shown to restore doxorubicin sensitivity in resistant breast cancer cells, establishing functional relevance. Building on these findings, a publicly accessible online server with a graphical user interface was further developed for the validated workflow of TAME-VS, enabling reproducible application by the broader community.
PMID:
42297903
Bibliographic data and abstract were imported from PubMed on 16 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0